GlassScriptPhysician profile
Azeem M Ahsan
NPI 1861543985
$6,358.97
in general payments reported to CMS, 2019-2025
32 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 92% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $522 · 2021: $666 · 2022: $694 · 2023: $1,258 · 2024: $1,322 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,830.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $940.24 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $808.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $695.41 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $615.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $420.46 | 2022-2025 | Linzess, Vraylar, Viberzi |
| Astellas Pharma US INC | $369.95 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.25 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Pfizer INC. | $326.52 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $294.46 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $247.03 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Medtronic, INC. | $170.43 | 2023 | Intellis Adaptivestim |
| Dexcom, INC. | $154.63 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $149.65 | 2019-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $136.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $114.82 | 2022-2025 | Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.07 | 2021-2022 | |
| Amarin Pharma, INC. | $74.76 | 2019-2021 | |
| Amgen INC. | $56.54 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $46.83 | 2022-2023 | |
| Axsome Therapeutics, INC. | $41.90 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $36.28 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $36.05 | 2019-2021 | |
| Phadia US INC. | $35.60 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $32.60 | 2019 | |
| Inspire Medical Systems, INC. | $25.71 | 2024 | Inspire |
| Amneal Pharmaceuticals LLC | $24.07 | 2021 | |
| Allergan, INC. | $20.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.16 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $17.14 | 2019 | |
| Boston Scientific Corporation | $16.60 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.36 | 2019 | |
| Vistapharm, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azeem Ahsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.